Dr. James Karlowsky

Dr. James A. Karlowsky

Professor, Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba

Provincial Medical Director, Clinical Microbiology, Diagnostic Services, Shared Health Manitoba

Degrees: B.Sc.[Pharmacy] (Manitoba, 1991), Ph.D. [Medical Microbiology] (Manitoba, 1996)

Postdoctoral Fellowships: Pharmacy (Manitoba, 1998), Medical Microbiology (Iowa, 2005)

Professional Certifications/Awarded Fellowships: D[ABMM] (2005), F[CCM] (2005), F[IDSA] (2007), F[AAM] (2015)

Office address: Department of Clinical Microbiology, Saint Boniface Hospital, 409 Taché Avenue, L4025-10, Winnipeg, Manitoba, R2H 2A6, Canada

Office telephone: (204) 237 2105; E-mail: jkarlowsky@sharedhealthmb.ca

Research Interests:

Antimicrobial resistance, clinical microbiology methods

Recent Publications:

1. Karlowsky JA, Adam HJ, Baxter MR, Denisuik AJ, Lagacé-Wiens PRS, Walkty AJ, Puttagunta S, Dunne MW, Zhanel GG. In vitro activity of sulopenem, an oral penem, against urinary isolates of Escherichia coli. Antimicrobial Agents and Chemotherapy, 2019;63(1):e01832-18.

2. Karlowsky JA, Hackel MA, Tsuji M, Yamano Y, Echols R, Sahm DF. In vitro activity of cefiderocol, a siderophore cephalosporin, against Gram-negative bacilli isolated by clinical laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015. International Journal of Antimicrobial Agents, 2019;53(4):456-466.

3. Karlowsky JA, Kazmierczak KM, Bouchillon SK, de Jonge BLM, Stone GG, Sahm DF. In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa collected in Latin American countries: INFORM global surveillance 2012-2015. Antimicrobial Agents and Chemotherapy, 2019; 63(4):e01814-18.

4. Karlowsky JA, Lagacé-Wiens PRS, Adam HJ, Baxter MR, Laing NM, Walkty AJ, Zhanel GG. In vitro susceptibility of urinary Escherichia coli isolates to first- and second-line empirically prescribed oral antimicrobials: CANWARD surveillance study results for Canadian outpatients, 2007-2016. International Journal of Antimicrobial Agents, 2019;54(1):62-68.

5. Karlowsky JA, Lob SH, Young K, Motyl MR, Sahm DF. Activity of imipenem-relebactam against multidrug-resistant Pseudomonas aeruginosa from the United States – SMART 2015-2017. Diagnostic Microbiology and Infectious Disease, 2019;95(2):212-215.

6. Karlowsky JA, Steenbergen JN, Zhanel GG. Microbiology and preclinical review of omadacycline. Clinical Infectious Diseases, 2019;69(Supplement 1):S6-S15.

7. Walkty AJ, Karlowsky JA, Baxter MR, Adam HJ, Boyd D, Bharat A, Mulvey MR, Charles M, Bergevin M, Zhanel GG. Frequency of 16S ribosomal RNA methyltransferase detection among Escherichia coli and Klebsiella pneumoniae clinical isolates obtained from patients in Canadian hospitals (CANWARD, 2013-2017). Diagnostic Microbiology and Infectious Diseases, 2019;94(2):199-201.

8. Walkty A, Karlowsky JA, Zarychanski R, Kadkhoda, Lagacé-Wiens P. Marked elevation of serum ferritin associated with Anaplasma phagocytophilum infection. Journal of the Association of Medical Microbiology and Infectious Diseases Canada, 2019;4(1):37-41.

9. Zhanel GG, Adam HJ, Baxter MR, Fuller J, Nichol KA, Denisuik A, Golden A, Hink R, Lagacé-Wiens P, Walkty A, Mulvey MR, Schweizer F, Bay D, Hoban DJ, Karlowsky JA. 42,936 pathogens from Canadian hospitals; 10 years of results (2007-16) from the CANWARD surveillance study. Journal of Antimicrobial Chemotherapy, 2019;74(Supplement 4):iv5-iv21.

10. Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, Idowu T, Domalaon R, Schweizer F, Zhanel MA, Lagacé-Wiens PRS, Walkty AJ, Noreddin A, Lynch JP, Karlowsky JA. Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant Gram-negative bacilli. Drugs, 2019;79(3):271-289.